Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer

Biomaterials

Volumn 92, Issue , 2016, Pages 71-80

  Uddin, Md Jashim ^a   Werfel, Thomas A ^b   Crews, Brenda C ^a   Gupta, Mukesh K ^b   Kavanaugh, Taylor E ^b   Kingsley, Philip J ^a   Boyd, Kelli ^a   Marnett, Lawrence J ^a   Duvall, Craig L ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Cancer; COX 2; Inflammation; Molecular imaging; Nanoparticles; Reactive oxygen species

Indexed keywords

BINDING SITES; BINS; FLUORESCENCE; HISTOLOGY; MAMMALS; MOLECULAR IMAGING; MOLECULAR OXYGEN; NANOPARTICLES; PATHOLOGY; SIGNAL TO NOISE RATIO; TISSUE; TUMORS; VISUALIZATION;

CANCER; CLINICAL TRANSLATION; COX-2; INFLAMMATION; INFLAMMATORY DISEASE; MICELLAR NANOPARTICLES; REACTIVE OXYGEN SPECIES; SELECTIVE INHIBITORS;

DISEASES;

CARRAGEENAN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROCOXIB A; INDOMETACIN; NANOPARTICLE; POLYMER; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; RHODAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SOLUBILITY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SIGNAL NOISE RATIO; TUMOR XENOGRAFT; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOLECULAR IMAGING; NUDE MOUSE; PHOTON CORRELATION SPECTROSCOPY; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DYNAMIC LIGHT SCATTERING; FEMALE; HUMANS; INDOLES; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR IMAGING; NANOPARTICLES; NEOPLASMS; POLYMERS; RHODAMINES; TISSUE DISTRIBUTION;

EID: 84961901640     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.028     Document Type: Article

References (51)

1. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 232-235.
2. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 271:33157-33160.
3. Li G., Yang T., Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem. Biophys. Res. Commun. 2002, 299:886-890.
4. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 1998, 90:1609-1620.
5. Gupta R.A., DuBois R.N. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J. Natl. Cancer Inst. 2002, 94:406-407.
6. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 2004, 67:1469-1478.
7. Uddin M.J., Crews B.C., Blobaum A.L., Kingsley P.J., Gorden D.L., McIntyre J.O., Matrisian L.M., Subbaramaiah K., Dannenberg A.J., Piston D.W. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010, 70:3618-3627.
8. Cekanova M., Uddin M.J., Legendre A.M., Galyon G., Bartges J.W., Callens A., Martin-Jimenez T., Marnett L.J. Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model. J. Biomed. Opt. 2012, 17:116002.
9. Cekanova M., Uddin M.J., Bartges J.W., Callens A., Legendre A.M., Rathore K., Wright L., Carter A., Marnett L.J. Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo. Cancer Prev. Res. 2013, 6:466-476.
10. Ra H., González-González E., Uddin M.J., King B.L., Lee A., Ali-Khan I., Marnett L.J., Tang J.Y., Contag C.H. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia 2015, 17:201-207.
11. Levin B., Lieberman D.A., McFarland B., Smith R.A., Brooks D., Andrews K.S., Dash C., Giardiello F.M., Glick S., Levin T.R., Pickhardt P., Rex D.K., Thorson A., Winawer S.J. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology*†. CA Cancer J. Clin. 2008, 58:130-160.
12. Heresbach D., Barrioz T., Lapalus M., Coumaros D., Bauret P., Potier P., Sautereau D., Boustière C., Grimaud J., Barthélémy C. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008, 40:284-290.
13. Hashimoto C.L., Iriya K., Baba E.R., Navarro-Rodriguez T., Zerbini M.C., Eisig J.N., Barbuti R., Chinzon D., Moraes-Filho J.P.P. Lugol's dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am. J. Gastroenterol. 2005, 100:275-282.
14. Bogomoletz W.V., Molas G., Gayet B., Potet F. Superficial squamous cell carcinoma of the esophagus. A report of 76 cases and review of the literature. Am. J. Surg. Pathol. 1989, 13:535-546.
15. Foresman W.H., Messing E.M. Bladder cancer: natural history, tumor markers, and early detection strategies. Seminars Surg. Oncol. 1997, 13:299-306.
16. Eetezadi S., Ekdawi S.N., Allen C. The challenges facing block copolymer micelles for cancer therapy: in vivo barriers and clinical translation. Adv. Drug Deliv. Rev. 2015, 91:7-22.
17. Hubbell J.A., Chilkoti A. Nanomaterials for drug delivery. Science 2012, 337:303-305.
18. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release 2010, 148:135-146.
19. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Ipe B.I., Bawendi M.G., Frangioni J.V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25:1165-1170.
20. Yamamoto Y., Nagasaki Y., Kato Y., Sugiyama Y., Kataoka K. Long-circulating poly (ethylene glycol)-poly (d, l-lactide) block copolymer micelles with modulated surface charge. J. Control Release 2001, 77:27-38.
21. Kim T.H., Youn Y.S., Jiang H.H., Lee S., Chen X., Lee K.C. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects. Bioconjugate Chem. 2011, 22:1631-1637.
22. Papahadjopoulos D., Allen T., Gabizon A., Mayhew E., Matthay K., Huang S., Lee K., Woodle M., Lasic D., Redemann C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. 1991, 88:11460-11464.
23. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
24. Maeda H., Nakamura H., Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
25. Napoli A., Valentini M., Tirelli N., Müller M., Hubbell J.A. Oxidation-responsive polymeric vesicles. Nat. Mater. 2004, 3:183-189.
26. Winterbourn C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008, 4:278-286.
27. Gao W., Chan J.M., Farokhzad O.C. pH-responsive nanoparticles for drug delivery. Mol. Pharm. 2010, 7:1913-1920.
28. Chien M.-P., Thompson M.P., Barback C.V., Ku T.-H., Hall D.J., Gianneschi N.C. Enzyme-directed assembly of a nanoparticle probe in tumor tissue. Adv. Mater. 2013, 25:3599-3604.
29. Callmann C.E., Barback C.V., Thompson M.P., Hall D.J., Mattrey R.F., Gianneschi N.C. Therapeutic enzyme-responsive nanoparticles for targeted delivery and accumulation in tumors. Adv. Mater. 2015, 27:4611-4615.
30. Nguyen M.M., Carlini A.S., Chien M.-P., Sonnenberg S., Luo C., Braden R.L., Osborn K.G., Li Y., Gianneschi N.C., Christman K.L. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv. Mater. 2015, n/a-n/a.
31. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F.W., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 2010, 27:2569-2589.
32. Convertine A.J., Benoit D.S., Duvall C.L., Hoffman A.S., Stayton P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. J. Control Release 2009, 133:221-229.
33. Nelson C.E., Kintzing J.R., Hanna A., Shannon J.M., Gupta M.K., Duvall C.L. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano 2013, 7:8870-8880.
34. Gupta M.K., Meyer T.A., Nelson C.E., Duvall C.L. Poly(PS-b-DMA) micelles for reactive oxygen species triggered drug release. J. Control Release 2012, 162:591-598.
35. Hu P., Tirelli N. Scavenging ROS: superoxide dismutase/catalase mimetics by the use of an oxidation-sensitive nanocarrier/enzyme conjugate. Bioconjugate Chem. 2012, 23:438-449.
36. Coutinho P.J., Castanheira E.M., Ceu Rei M., Real Oliveira M.E.C. Nile Red and DCM fluorescence anisotropy studies in C12E7/DPPC mixed systems. J. Phys. Chem. B 2002, 106:12841-12846.
37. Gupta M.K., Martin J.R., Werfel T.A., Shen T., Page J.M., Duvall C.L. Cell protective, ABC triblock polymer-based thermoresponsive hydrogels with ROS-triggered degradation and drug release. J. Am. Chem. Soc. 2014, 136:14896-14902.
38. Poole K.M., Nelson C.E., Joshi R.V., Martin J.R., Gupta M.K., Haws S.C., Kavanaugh T.E., Skala M.C., Duvall C.L. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease. Biomaterials 2015, 41:166-175.
39. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J. Biol. Chem. 1999, 274:22903-22906.
40. Surh Y.-J., Chun K.-S., Cha H.-H., Han S.S., Keum Y.-S., Park K.-K., Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2001, 480-481:243-268.
41. Gao W., Liu W., Mackay J.A., Zalutsky M.R., Toone E.J., Chilkoti A. In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15231-15236.
42. Gao W., Liu W., Christensen T., Zalutsky M.R., Chilkoti A. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc. Natl. Acad. Sci. 2010, 107:16432-16437.
43. di Meglio P., Ianaro A., Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-κB activation. Arthritis Rheum. 2005, 52:951-958.
44. Weissleder R., Ntziachristos V. Shedding light onto live molecular targets. Nat. Med. 2003, 9:123-128.
45. Tanabe K., Zhang Z., Ito T., Hatta H., Nishimoto S. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org. Biomol. Chem. 2007, 5:3745-3757.
46. Scheuer W., van Dam G.M., Dobosz M., Schwaiger M., Ntziachristos V. Drug-based Optical Agents: Infiltrating Clinics at Lower Risk 2012.
47. Bruckman M.A., Jiang K., Simpson E.J., Randolph L.N., Luyt L.G., Yu X., Steinmetz N.F. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. Nano Lett. 2014, 14:1551-1558.
48. Zheng J., Muhanna N., De Souza R., Wada H., Chan H., Akens M.K., Anayama T., Yasufuku K., Serra S., Irish J., Allen C., Jaffray D. A multimodal nano agent for image-guided cancer surgery. Biomaterials 2015, 67:160-168.
49. Zheng J., Allen C., Serra S., Vines D., Charron M., Jaffray D.A. Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology. Contrast Media Mol. Imaging 2010, 5:147-154.
50. Steinmetz N.F., Ablack A.L., Hickey J.L., Ablack J., Manocha B., Mymryk J.S., Luyt L.G., Lewis J.D. Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing peptide receptors. Small 2011, 7:1664-1672.
51. Uddin M.J., Crews B.C., Ghebreselasie K., Daniel C.K., Kingsley P.J., Xu S., Marnett L.J. Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe. J. Biomed. Opt. 2015, 20. 050502-050502.